AP10 Recard Proposition of the type of type of the type of type of

FORM			Application Number		10/533,764		
			Filing Date		May 4, 2005		
			First Named Inventor		William Brown		
			Art Unit		To Be Determined		
FRADE Used for all correspondence after initial filing)			Examiner Name	Examiner Name		To Be Determined	
Total Number of Pages in Thi		iiiig)	Attorney Docket No	ımber	ASZN0036-100 (	(100884-1P US)	フ
	ENCLOSURES (check all that apply)						=
Fee Transmittal Form Drawing(s				After Allowance Com	munication to TC		
		Licensing	i-related Papers		Appeal Communication to Board of Appeals and Interferences		
Amendment / Reply		Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final			Convert to a al Application		Proprietary Information		
			Attorney, Revocation of Correspondence		Status Letter		
Extension of Time Requ	est	Terminal	Disclaimer		Other Enclosure(s)		
Express Abandonment Request		•	Assi		atement under 37 CFR 3.73(b) with copy of ssignment executed by ALL inventors to straZeneca AB (3 pp. total)		:
☐ Information Disclosure Statement		☐ Landscape Table on CD		Astr	Astrazeneta Ab (5 pp. total)		
Certified Copy of Priority Document(s)		marks					$\neg$
Reply to Missing Parts/ Incomplete Application							
Reply to Missing Parts under 37 CFR1.52 or 1.53							
	SIGNATU	JRE OF	APPLICANT, ATTO	RNEY, O	R AGENT		
Firm Cozen O'Conno							
Signature Par		Pan	ek famel				
Printed Name Paul K. Leg		l K. Legaar					
Date 30 Nav		anser 2007	Reg. No.	38,534			
	CE	RTIFICA	TE OF TRANSMISS	ION/MAI	LING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.							
Signature	P	AC A	0				•
Typed or printed name	Typed or printed name Paul K. Legaard, Ph.D., Registration No. 38,534 Date 30 November 2007					)2 <sub>7</sub>	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DEC 0 2 2005 Under the Paperwork
TRADENA Reduction Act of 1995, no persons are

PTO/SB/81 (11-04)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

# **POWER OF ATTORNEY** and **CORRESPONDENCE ADDRESS INDICATION FORM**

a required to respond to a collection	n of information unless it displays a valid OMB control number.
Application Number	10/533,764
Filing Date	May 4, 2005
First Named Inventor	William Brown
Title	4(PHENYL-PIPERAZINYL-METHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINESTINAL DISORDERS
Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket No.	ASZN0036-100 (100884-1P US)

I hereby revoke all previous powers of attorney given in the above-identified application.					
			ar in the abt		пинеч арричации.
I hereby appoint:				•	
☑ Practitioners associated with the Customer Number:  ○B			52286		
☐ Practitioner(s) na	amed below:				
	Name		Registration	n Numbe	er
				•	
				•	
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.					
Please recognize o	r change the correspondence address fo	r the abo	e-identified app	lication t	o:
The address as	ssociated with the above-mentioned Cust	omer Nu	nber		
OR			2.0 ···		
☐ The address a	ssociated with Customer Number:				
OR ·					
Firm <i>or</i> Individual Name					
Address				,	
City	2222	State		ZIP	
Country					
Telephone		Fax			
I am the:					
Applicant/Inventor.					
Assignee of record of the entire interest. See 37 CFR 3.71.					
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)					
-	SIGNATURE of Applic	ant or As	<del></del>	ora	7 O-t-b- 2005
Signature	Jun 2		Date		3 October 2005
Name	Anna-Lena Rosendahl		Telephone	<u></u>	
Title and Company Director IP Services, AstraZeneca AB  NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if					
more than one signature	more than one signature is required, see below.				
*Total of forms are submitted.					

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form endor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

#### **PATENT**

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Brown and Griffin

Serial No.: 10/533,764 Art Unit: To Be Determined

Filing Date: May 4, 2005 Examiner: To Be Determined

For: 4(PHENYL-PIPERAZINYL-METHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINESTINAL

DISORDERS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## STATEMENT UNDER 37 CFR 3.73(b)

Applicant or Patent Owner, ASTRAZENECA AB, a company created and existing under the laws of Sweden, of Application No. 10/533,764 filed on May 4, 2005 and entitled 4(PHENYL-PIPERAZINYL-METHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINESTINAL DISORDERS, states that it is:

$\square$	the assignee of the entire right, title, and interest; or an assignee of less than the entire right, title, and interest.
	extent (by, percentage) of its ownership interest is 100% in the patent n/patent identified above by virtue of either:
X	A copy of the assignment from the inventor(s) of the patent application identified above is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,

AstraZeneca AB

Date: 3 October 2005

Name: Anna-Lena Rosendahl Title: Director IP Services

ATTORNEY DOCKET NO.: AstraZeneca Ref.: 100884-1P US

#### **ASSIGNMENT**

Now, therefore, for good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, I/we

William BROWN and Andrew GRIFFIN both of of AstraZeneca R&D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Quebec H4S 1Z9, Canada;

hereafter referred to as ASSIGNOR (S),

Hereby sell(s), assign(s) and transfer(s) to ASSIGNEE **AstraZeneca AB**, a company created and existing under the laws of Sweden, having its Head Office at SE-151 85 Södertalje, Sweden, and the successors, assigns and legal representatives of the ASSIGNEE, the entire right, title and interest for the United States and its territorial possessions, and in all foreign countries, in and to the inventions and any and all improvements thereon which are the subject of an application entitled:

# 4(PHENYL-PIPERAZINYL-METHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS

And which is disclosed in:

a) 🔲	U.S. patent application executed on even date herewith;
b) 🔲	U.S. patent application executed on;
c) 🗌	U.S. application no;
d) 🔯	International application no. PCT/SE2003/001706 filed on 5 November 2003.

And in and to the above application and any legal equivalent thereof in a foreign country, including the right to claim priority, and in and to any division, continuation or continuation-in-part, renewal or substitute thereof, and in and to all resulting Letters Patents or any reissue or reexamination thereof, to have and to hold the same to the full end of the term or terms for which any and all of said Letters Patent may be granted;

ASSGNOR(S) authorize(s) and request(s) the issuing authority to issue any and all patents on said application or applications to said ASSIGNEE or its successors and assigns;

ASSIGNOR(S) hereby covenant(s) that ASSIGNOR(S) has/have the full power to make this assignment, and that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment; and

Without further payment or compensation by the ASSIGNEE or its successors and assigns, ASSIGNOR(S) further covenant(s) and agree(s) to communicate to said ASSIGNEE or its representatives, agents, its successors or assigns, any facts relating to said invention or inventions including evidence for purposes of interference or other administrative or legal proceedings whenever requested; to testify in any interference, legal or administrative proceedings, whenever requested; to execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective; and to do everything possible to aid said ASSIGNEE, its successors or assigns and nominees to secure, obtain and enforce proper patent protection for said invention or inventions in this or any foreign country.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

IN WITNESS WHEREOF, I have hereunto set my hand	d and seal on the date below written.
William BROWN Signature of Assignor	Date of Assignor's Signature
WITNESSED BY:  Signature of Witness Name of Witness (Type or print clearly)  CAROLE BUSIN KASZE	Signature of Witness MARIE LE FRANÇOIS (Type or print clearly)
IN WITNESS WHEREOF, I have hereunto set my hand  Andrew GRIFFIN Signature of Assignor	19th April 2005
WITNESSED BY:  Signature of Witness Name of Witness (Type or print clearly)	Date of Assignor's Signature  Signature of Witness MARIE LE FRANCOIS  (Type or print clearly)
Additional signature pages attached: Yes No	
Additional signature pages attached: Yes No	